The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction

Eugenio Ventimiglia, Paolo Capogrosso, Francesco Montorsi, Andrea Salonia

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Introduction: Phosphodiesterase type 5 inhibitors (PDE5Is) are the leading drugs for the treatment of erectile dysfunction (ED), being recommended as a first line treatment by both the European and US urological guidelines. PDE5Is are highly effective as compared to placebo, well tolerated and have a very low, though not negligible, rate of severe treatment-related adverse events.Areas covered: This paper reviews the safety profile of currently available PDE5Is, comparing them in a broad spectrum ED population and outlining a number of real-life aspects of importance in the real-life everyday clinical setting.Expert opinion: Guidelines unanimously agree in considering PDE5Is as first line treatments for ED when well-tolerated and not contraindicated. Despite the fact that no high-grade evidence comparing the efficacy and the safety for PDE5Is is currently available, published data seem to suggest that there are no major differences in their safety proles. Moreover, although oral PDE5Is were shown to cause more AEs than placebo, they were generally mild and well tolerated.

Original languageEnglish
Pages (from-to)141-152
Number of pages12
JournalExpert Opinion on Drug Safety
Volume15
Issue number2
DOIs
Publication statusPublished - Feb 1 2016

Fingerprint

Phosphodiesterase 5 Inhibitors
Erectile Dysfunction
Safety
Placebos
Guidelines
Expert Testimony
Therapeutics
Pharmaceutical Preparations
Population

Keywords

  • adverse events
  • avanafil
  • Erectile dysfunction
  • lodenafil
  • mirodenafil
  • phophodiesterase type 5 inhibitors
  • safety
  • sildenafil
  • tadalafil
  • udenafil
  • vardenafil

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction. / Ventimiglia, Eugenio; Capogrosso, Paolo; Montorsi, Francesco; Salonia, Andrea.

In: Expert Opinion on Drug Safety, Vol. 15, No. 2, 01.02.2016, p. 141-152.

Research output: Contribution to journalArticle

@article{dad40eb3f2bd43778a79c02999641b80,
title = "The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction",
abstract = "Introduction: Phosphodiesterase type 5 inhibitors (PDE5Is) are the leading drugs for the treatment of erectile dysfunction (ED), being recommended as a first line treatment by both the European and US urological guidelines. PDE5Is are highly effective as compared to placebo, well tolerated and have a very low, though not negligible, rate of severe treatment-related adverse events.Areas covered: This paper reviews the safety profile of currently available PDE5Is, comparing them in a broad spectrum ED population and outlining a number of real-life aspects of importance in the real-life everyday clinical setting.Expert opinion: Guidelines unanimously agree in considering PDE5Is as first line treatments for ED when well-tolerated and not contraindicated. Despite the fact that no high-grade evidence comparing the efficacy and the safety for PDE5Is is currently available, published data seem to suggest that there are no major differences in their safety proles. Moreover, although oral PDE5Is were shown to cause more AEs than placebo, they were generally mild and well tolerated.",
keywords = "adverse events, avanafil, Erectile dysfunction, lodenafil, mirodenafil, phophodiesterase type 5 inhibitors, safety, sildenafil, tadalafil, udenafil, vardenafil",
author = "Eugenio Ventimiglia and Paolo Capogrosso and Francesco Montorsi and Andrea Salonia",
year = "2016",
month = "2",
day = "1",
doi = "10.1517/14740338.2016.1131818",
language = "English",
volume = "15",
pages = "141--152",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Taylor and Francis Ltd.",
number = "2",

}

TY - JOUR

T1 - The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction

AU - Ventimiglia, Eugenio

AU - Capogrosso, Paolo

AU - Montorsi, Francesco

AU - Salonia, Andrea

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Introduction: Phosphodiesterase type 5 inhibitors (PDE5Is) are the leading drugs for the treatment of erectile dysfunction (ED), being recommended as a first line treatment by both the European and US urological guidelines. PDE5Is are highly effective as compared to placebo, well tolerated and have a very low, though not negligible, rate of severe treatment-related adverse events.Areas covered: This paper reviews the safety profile of currently available PDE5Is, comparing them in a broad spectrum ED population and outlining a number of real-life aspects of importance in the real-life everyday clinical setting.Expert opinion: Guidelines unanimously agree in considering PDE5Is as first line treatments for ED when well-tolerated and not contraindicated. Despite the fact that no high-grade evidence comparing the efficacy and the safety for PDE5Is is currently available, published data seem to suggest that there are no major differences in their safety proles. Moreover, although oral PDE5Is were shown to cause more AEs than placebo, they were generally mild and well tolerated.

AB - Introduction: Phosphodiesterase type 5 inhibitors (PDE5Is) are the leading drugs for the treatment of erectile dysfunction (ED), being recommended as a first line treatment by both the European and US urological guidelines. PDE5Is are highly effective as compared to placebo, well tolerated and have a very low, though not negligible, rate of severe treatment-related adverse events.Areas covered: This paper reviews the safety profile of currently available PDE5Is, comparing them in a broad spectrum ED population and outlining a number of real-life aspects of importance in the real-life everyday clinical setting.Expert opinion: Guidelines unanimously agree in considering PDE5Is as first line treatments for ED when well-tolerated and not contraindicated. Despite the fact that no high-grade evidence comparing the efficacy and the safety for PDE5Is is currently available, published data seem to suggest that there are no major differences in their safety proles. Moreover, although oral PDE5Is were shown to cause more AEs than placebo, they were generally mild and well tolerated.

KW - adverse events

KW - avanafil

KW - Erectile dysfunction

KW - lodenafil

KW - mirodenafil

KW - phophodiesterase type 5 inhibitors

KW - safety

KW - sildenafil

KW - tadalafil

KW - udenafil

KW - vardenafil

UR - http://www.scopus.com/inward/record.url?scp=84958149713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958149713&partnerID=8YFLogxK

U2 - 10.1517/14740338.2016.1131818

DO - 10.1517/14740338.2016.1131818

M3 - Article

AN - SCOPUS:84958149713

VL - 15

SP - 141

EP - 152

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 2

ER -